Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:FLGC NASDAQ:NXTC NASDAQ:ONVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.87-0.5%$4.20$1.42▼$75.00$14.16M0.66294,924 shs575,225 shsFLGCFlora Growth$24.01+0.9%$22.65$15.15▼$82.29$13.77M1.9710,360 shs5,809 shsNXTCNextCure$5.30-2.7%$5.12$2.69▼$19.20$14.56M1.2716,626 shs2,456 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie-0.53%+7.47%+10.00%-83.60%-93.53%FLGCFlora Growth+1.53%+6.23%+16.35%-17.06%-34.50%NXTCNextCure-2.67%+7.73%+2.02%-35.21%-67.32%ONVOOrganovo0.00%0.00%0.00%0.00%-69.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.87-0.5%$4.20$1.42▼$75.00$14.16M0.66294,924 shs575,225 shsFLGCFlora Growth$24.01+0.9%$22.65$15.15▼$82.29$13.77M1.9710,360 shs5,809 shsNXTCNextCure$5.30-2.7%$5.12$2.69▼$19.20$14.56M1.2716,626 shs2,456 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie-0.53%+7.47%+10.00%-83.60%-93.53%FLGCFlora Growth+1.53%+6.23%+16.35%-17.06%-34.50%NXTCNextCure-2.67%+7.73%+2.02%-35.21%-67.32%ONVOOrganovo0.00%0.00%0.00%0.00%-69.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 4.00Strong BuyN/AN/AFLGCFlora Growth 3.00Buy$93.00287.27% UpsideNXTCNextCure 2.67Moderate Buy$25.50381.59% UpsideONVOOrganovo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONVO, BIVI, FLGC, and NXTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025FLGCFlora GrowthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$30.007/15/2025NXTCNextCurePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$36.00 ➝ $15.007/8/2025NXTCNextCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/1/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$9.93 per shareN/AFLGCFlora Growth$59.51M0.23N/AN/A$12.21 per share1.97NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/AONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$17.54M-$79.10N/A∞N/AN/A-89.02%-75.32%9/29/2025 (Estimated)FLGCFlora Growth-$15.91M-$34.38N/AN/AN/A-24.86%-261.57%-48.06%11/12/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)ONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/ALatest ONVO, BIVI, FLGC, and NXTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/A8/1/2025Q2 2025FLGCFlora Growth-$0.06-$0.11-$0.05-$0.11$11.77 million$14.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.109.10FLGCFlora Growth0.500.960.61NXTCNextCureN/A3.713.71ONVOOrganovoN/A0.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%FLGCFlora Growth36.01%NXTCNextCure42.65%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%FLGCFlora Growth12.56%NXTCNextCure17.90%ONVOOrganovo3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie107.53 million7.35 millionNo DataFLGCFlora Growth280580,000506,000Not OptionableNXTCNextCure902.68 million2.20 millionOptionableONVOOrganovo201.70 million14.79 millionOptionableONVO, BIVI, FLGC, and NXTC HeadlinesRecent News About These CompaniesDriven! The Onvo L60 Is China’s Best Tesla Model Y Killer to DateMay 18, 2025 | msn.comTwo new option listings and one option delisting on April 24thApril 25, 2025 | markets.businessinsider.comVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ MarketApril 24, 2025 | globenewswire.comOrganovo announces VivoSim to carry forward 3D bioprinting, legacy techApril 23, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol "VIVS"April 23, 2025 | quiverquant.comQVivoSim to Carry Forward Organovo 3D BioprintingApril 23, 2025 | globenewswire.comOrganovo expects to meet requirements for continued listing on NasdaqApril 2, 2025 | markets.businessinsider.comOrganovo Holdings Expects to Meet Nasdaq Listing RequirementsApril 2, 2025 | tipranks.comOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | financialpost.comFOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | globenewswire.comOrganovo sees cash runway through the end of FY26March 28, 2025 | markets.businessinsider.comOrganovo, Inc.: Organovo Provides Business UpdateMarch 27, 2025 | finanznachrichten.deOrganovo Provides Business UpdateMarch 27, 2025 | financialpost.comFOrganovo Provides Business UpdateMarch 27, 2025 | globenewswire.comOrganovo, Inc.: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 26, 2025 | finanznachrichten.deOrganovo closes sale of FXR program to Eli LillyMarch 25, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Completes Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | quiverquant.comQOrganovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | globenewswire.comOrganovo Announces 1-for-12 Reverse Stock Split To Maintain Nasdaq ComplianceMarch 21, 2025 | nasdaq.comOrganovo trading halted, news pendingMarch 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONVO, BIVI, FLGC, and NXTC Company DescriptionsBioVie NASDAQ:BIVI$1.87 -0.01 (-0.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.90 +0.02 (+1.34%) As of 09/12/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Flora Growth NASDAQ:FLGC$24.01 +0.21 (+0.90%) Closing price 09/12/2025 03:58 PM EasternExtended Trading$24.22 +0.21 (+0.88%) As of 09/12/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.NextCure NASDAQ:NXTC$5.30 -0.15 (-2.67%) Closing price 09/12/2025 03:50 PM EasternExtended Trading$5.38 +0.08 (+1.51%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
